AUTHOR=Han Xu , Yu Ting , Chen Xi , Du Zhiyan , Yu Man , Xiong Jiang 

TITLE=Effect of Astragalus membranaceus on left ventricular remodeling in HFrEF: a systematic review and meta-analysis

JOURNAL=Frontiers in Pharmacology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1345797

DOI=10.3389/fphar.2024.1345797

ISSN=1663-9812

ABSTRACT=<p><bold>Background:</bold> Left ventricular remodeling (LVR) is a key factor leading to the onset and progression of heart failure with reduced ejection fraction (HFrEF). Improving LVR can delay the progression of HFrEF and improve quality of life.</p><p><bold>Objective:</bold> To evaluate the improvement effect of <italic>Astragalus membranaceus (A. membranaceus)</italic> on LVR in patients with HFrEF.</p><p><bold>Method:</bold> We retrieved randomized controlled trials (RCTs) of <italic>A. membranaceus</italic> in treating HFrEF from eight Chinese and English databases, up until 31 October 2023. To assess the quality of the literature, we utilized the bias risk tool from the Cochrane Handbook. For meta-analysis, we employed Review Manager 5.4.1 software. Additionally, we performed sensitivity analysis and publication bias assessment using Stata 17.0 software.</p><p><bold>Result:</bold> Totally 1,565 patients were included in 19 RCTs. Compared to conventional treatment (CT), the combination therapy of <italic>A. membranaceus</italic> with CT demonstrated significant improvements in LVR, specifically increasing left ventricular ejection fraction (LVEF, MD = 5.82, 95% CI: 4.61 to 7.03, <italic>p</italic> &lt; 0.00001), decreasing left ventricular end-diastolic diameter (LVEDD, MD = −4.05, 95% CI: −6.09 to −2.01, <italic>p</italic> = 0.0001), and left ventricular end-systolic diameter (LVESD, MD = −12.24, 95% CI: −15.24 to −9.24, <italic>p</italic> &lt; 0.00001). The combination therapy of <italic>A. membranaceus</italic> with CT also improved clinical efficacy (RR = 4.81, 95% CI: 3.31 to 7.00, <italic>p</italic> &lt; 0.00001), reduced brain natriuretic peptide (BNP, MD = −113.57, 95% CI: −146.91 to −81.22, <italic>p</italic> &lt; 0.00001) level, and increased 6-min walking distance (6-MWD, MD = 67.62, 95% CI: 41.63 to 93.60, <italic>p</italic> &lt; 0.00001). In addition, the combination therapy of <italic>A. membranaceus</italic> with CT mitigated inflammatory responses by reducing tumor necrosis factor-alpha (TNF-α, MD = −16.83, 95% CI: −22.96 to −10.71, <italic>p</italic> &lt; 0.00001), interleukin-6 (IL-6, MD = −29.19, 95% CI: −36.08 to −22.30, <italic>p</italic> &lt; 0.00001), and high-sensitivity C-reactive protein (hs-CRP, MD = −0.98, 95% CI: −1.43 to −0.52, <italic>p</italic> &lt; 0.0001). Notably, the combination therapy of <italic>A. membranaceus</italic> with CT did not increase the incidence of adverse reactions (RR = 0.86, 95% CI: 0.25 to 2.96, <italic>p</italic> = 0.81).</p><p><bold>Conclusion:</bold> This systematic review and meta-analysis revealed that the combination therapy of <italic>A. membranaceus</italic> with CT has more advantages than CT alone in improving LVR and clinical efficacy in HFrEF patients, without increasing the incidence of adverse reactions. However, due to the limited quality of included studies, more high-quality investigations are required to provide reliable evidence for clinical use.</p><p><bold>Systematic Review Registration:</bold><ext-link ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=397571" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=397571</ext-link>, Identifier: CRD42023397571.</p>